Demographic and medication information are shown for patients with SLE and healthy matched controls included in the study
| Patients with SLE (n=18) | Healthy controls (n=15) | Patients with RA (n=8) | |
|---|---|---|---|
| Demographics | |||
| Age (mean±SEM) | 37±3 | 38±4 | 49±4 |
| Sex | Female | Female | Female |
| SLEDAI (mean±SEM) | 6±1 | – | – |
| Medications | |||
| Azathioprine | 6% | – | – |
| Etanercept | – | – | 25% |
| Hydroxychloroquine | 67% | – | 63% |
| Methotrexate | 11% | – | 75% |
| Mycophenolate mofetil | 33% | – | – |
| Prednisone | 61% | – | 50% |
| Quinacrine | 17% | – | – |
| Rituximab | – | – | 25% |
| Sulfasalazine | – | – | 13% |
| Tocilizumab | – | – | 13% |
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.